DalsnaFinance › Analyst accuracy › Stifel › MIRM target
Citizens raises Mirum Pharmaceuticals stock price target on HDV data
maintained a Buy rating with a $136 price target following the release of topline data from the AZURE-1 trial
A fact about what Stifel published, as reported by Investing.com, not a recommendation from Dalsna Finance; Stifel is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.